$8.52
-0.11(-1.27%)
Mkt Cap $440M
$5.31
$15.98
52-Week Range
At a Glance
AI-generatedREGENXBIO Inc.
Revenue breakdown: License And Service (28.9%), Zolgensma And Itvisma Royalties (20%), Zolgensma Royalties (19.9%).
8-K
On March 18, 2026, REGENXBIO Inc. entered into a Settlement and Release Agreement with GlaxoSmithKline LLC to resolve a dispute over sublicense fees under their 2009 License Agreement. The Company will pay $10.0 million to GSK within three business days, securing mutual releases of past claims and certain future claims while continuing existing payment practices.$440M
Market Cap
$170M
Revenue
-$193M
Net Income
Employees353
Fundamentals
How The Business Makes Money
Revenue by Segment
License And Service28.9%($238M)
Zolgensma And Itvisma Royalties20%($165M)
Zolgensma Royalties19.9%($164M)
Nippon Shinyaku Licenses8.8%($73M)
License And Royalty Revenue8.8%($73M)
Zolgensma Royalties Itvisma6.4%($52M)
Service1.9%($16M)
Total Service Revenue1.9%($16M)
Nippon Shinyaku Services1.4%($12M)
Service Revenue1.4%($12M)
Other Service Revenue0.5%($4M)
Itvisma Royalties0.1%($641.0K)
Activity
What Changed Recently
Analyst View
Company Profile
CIK0001590877
ISINUS75901B1070
CUSIP75901B107
Phone240 552 8181
Address9804 Medical Center Drive, Rockville, MD, 20850, US
SEC EDGAR